US regulators approve first human pill derived from faecal matter
FDA gives green light to C. difficile treatment in boost for microbiome drug developers (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 26, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves Vowst (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI
CAMBRIDGE, Mass.& HOBOKEN, N.J.--(BUSINESS WIRE)--Apr. 26, 2023-- Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced the U.S. Food and Drug Administration (FDA) approval of Vowst (fecal microbiota... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 26, 2023 Category: Drugs & Pharmacology Source Type: news
Cochrane study finds stool transplants more effective than antibiotics for treating recurring, life-threatening gut infections
A new Cochrane Review has found that, compared with standard antibiotic treatment, stool transplantation can increase the number of people recovering from Clostridioides difficile (C. diff) infection, a condition which causes potentially life-threatening diarrhea. 77 percent of people who received a stool transplant did not experience reinfection within eight weeks, compared to 40 percent of those who received antibiotics alone.C. diff is a bacterium that can cause life-threatening diarrheal illness in individuals with an unhealthy mixture of gut bacteria, known as dysbiosis. The most common cause of dysbiosis is treatment...
Source: Cochrane News and Events - April 24, 2023 Category: Information Technology Authors: Muriah Umoquit Source Type: news
Stress ulcer prophylaxis in critically ill adult patients with sepsis at risk of gastrointestinal bleeding: a retrospective cohort study.
Conclusions: Among critically ill, septic, adult patients at risk for GI bleeding, SUP showed no e ffect on hospital mortality, the rate of GI bleeding, pneumonia, CDI and ICU LOS. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 11, 2023 Category: Consumer Health News Source Type: news
Possible C. difficile –Colon Cancer Connection: Study Possible C. difficile –Colon Cancer Connection: Study
Previous research has found that there is a higher amount of C diff in cancerous lesions than in healthy body tissue.WebMD Health News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 22, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Real-World Study Looks at Use of Bezlotoxumab, FMT for CDI Real-World Study Looks at Use of Bezlotoxumab, FMT for CDI
A single-center study suggests that FMT and bezlotoxumab ― two recommended therapies for recurrent C difficile infections ― are not commonly used in Spain, which doesn ' t appear to align with US practice.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 23, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news
Fecal Bile Acid to Predict Recurrence in C. Difficile Infection Fecal Bile Acid to Predict Recurrence in C. Difficile Infection
This study investigated how gut microbiota-bile acid interactions relate to the pathogenesis of C. difficile infection. Could fecal bile acids have potential as biomarkers to predict CDI recurrence?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
First FDA-Approved Fecal-Based Treatment Helps Fight C. difficile
THURSDAY, Dec. 1, 2022 -- The U.S. Food and Drug Administration on Wednesday approved the first fecal microbiota treatment, aimed at helping adults battling tough-to-treat Clostridioides difficile infections (CDIs). " Today ' s approval of Rebyota is... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 1, 2022 Category: General Medicine Source Type: news
Fecal-Based Treatment, Rebyota. Helps Fight C. difficile
THURSDAY, Dec. 1, 2022 -- The U.S. Food and Drug Administration on Wednesday approved the first fecal microbiota treatment, aimed at helping adults battling tough-to-treat Clostridioides difficile infections (CDIs). " Today ' s approval of Rebyota is... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 1, 2022 Category: General Medicine Source Type: news
FDA OKs First Fecal Transplant Therapy for Recurrent C difficile FDA OKs First Fecal Transplant Therapy for Recurrent C difficile
Rebyota, a microbiota-based live biotherapeutic prepared from human stool, is intended for use after an individual has completed antibiotic treatment for recurrent C difficile infection.FDA Approvals (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - December 1, 2022 Category: Internal Medicine Tags: Gastroenterology News Alert Source Type: news
First FDA-Approved Fecal-Based Treatment, Rebyota, Helps Fight a Tough Superbug
THURSDAY, Dec. 1, 2022 -- The U.S. Food and Drug Administration on Wednesday approved the first fecal microbiota treatment, aimed at helping adults battling tough-to-treat Clostridium difficile (C. diff) infections. " Today ' s approval of Rebyota is... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 1, 2022 Category: General Medicine Source Type: news
Learn To “See” C. Difficile To Protect Yourself From This Serious Infection
C. diff causes almost half a million infections yearly. Restoring normal gut microbiome is the focus of new treatments for C diff infections, which follow courses of antibiotics. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 28, 2022 Category: Pharmaceuticals Authors: Judy Stone, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news
Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?
Recently, the recommendations for the treatment of Clostridioides difficile infection (CDI) have been updated. However, in addition to the clinical efficacy data, the drug of choice should ideally represent optimal antimicrobial stewardship, with an emphasis on rapid restoration of the gut microbiota to minimize the risk of infection relapses. Oral administration of metronidazole results in low concentration in stool, and interaction with fecal microbiota reduces its antimicrobial bioactivity. Reported elevated minimum inhibitory concentrations of metronidazole in epidemic C. difficile ribotypes and the emergence of plasmi...
Source: Current Awareness Service for Health (CASH) - November 15, 2022 Category: Consumer Health News Source Type: news
Houston, We Have a Problem: Reports of Clostridioides difficile Isolates With Reduced Vancomycin Susceptibility.
During the past 4 decades, oral vancomycin has been a mainstay of Clostridioides difficile infection (CDI) therapy with no reports of treatment failure due to emergence of vancomycin resistance. However, C. difficile isolates with high-level phenotypic resistance to vancomycin have recently been reported in 3 distinct geographic regions. There is an urgent need for surveillance to determine if strains with reduced vancomycin susceptibility are circulating in other areas. In a Cleveland-area hospital, screening of 176 CDI stool specimens yielded no C. difficile isolates with reduced vancomycin susceptibility and highlighted...
Source: Current Awareness Service for Health (CASH) - November 15, 2022 Category: Consumer Health News Source Type: news
13 Highlights From ACG 2022 13 Highlights From ACG 2022
Dr David Johnson shares the latest data from this year ' s meeting, which range from novel treatments for C difficile to the use of virtual reality in treating dyspepsia.Medscape Gastroenterology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 1, 2022 Category: Allergy & Immunology Tags: Gastroenterology Commentary Source Type: news
